Rob Neville provides an overview of Savara Pharmaceuticals, a company focused on rare respiratory diseases. Savara is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases.
Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field.
Pipeline includes the following:
Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for pulmonary alveolar proteinosis (PAP).
AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis.
Aironite, an inhaled sodium nitrite for HFpEF in Phase 2 development.
Molgradex is currently in Phase 3 development for PAP and in preparation for Phase 2a development for NTM lung infection.